English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain

Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusCompleted
Sponsors
University of Saskatchewan

Keywords

Abstract

Oral medications like gabapentin and acetaminophen are commonly given to patients prior to surgery to provide balanced anaesthesia. Intravenous methadone has been shown to decrease postoperative pain as well as postoperative nausea and vomiting, which are known barriers to discharge. Oral methadone would be a convenient alternative to give as a preoperative medication with its bioavailability approaching 80%. No clinical trials to date have explored the utility of oral methadone as a preoperative analgesic to improve postoperative outcomes. Current literature shows preoperative IV methadone reduces opioid consumption in the perioperative period for cardiac surgeries; therefore, investigators hypothesize that preoperative oral methadone will also reduce postoperative pain and opioid consumption in patients undergoing sternotomy for cardiac surgery.

Description

Investigators propose a prospective, randomized, double-blind, placebo-controlled trial to investigate the effects of preoperative oral methadone on postoperative pain. The trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and University of Saskatchewan Research Ethics Committee principles using an intent-to-treat model. The primary endpoint will be postoperative pain in the ICU, and secondary outcomes will include morphine requirements as measured by Patient Controlled Analgesia (PCA). Secondary endpoints include opioid consumption at 15 minutes and at 2, 4, 8, 12, 24, 48, and 72 hours post extubation. Other secondary endpoints include the following: pain with cough (using a 0-10 verbal pain scale) measured at the time of extubation then daily until post-op day three. Secondary outcomes that will be recorded from nursing assessment records include: incidence of nausea and/or vomiting requiring antiemetics, pruritus, hypoventilation (respiratory rate less than 8 breaths/min), hypoxemia (oxygen saturation less than 90%), time to extubation, and sedation (Richmond Agitation-Sedation Scale of -4 or -5).

Patients will receive a dose of either oral methadone or placebo prior to entering the operating room. The dose given will be 0.3 mg/kg (to a maximum of 30 mg) or equivalent volume of placebo. An blinded research assistant will receive an envelope the morning of surgery outlining if the patient is in group A or B as well as their weight in kg. For the methadone arm the research assistant will prepare the appropriate amount of methadone, which is dispensed as 10 mg/mL, and dilute it to a total volume of 5 mL in sugary syrup to mask its taste. For the placebo arm a similar volume will be mixed at a 0.3 mg/kg volume and diluted to a total volume of 5 mL of sugary syrup. The methadone or placebo will be given to the researcher in a syringe. The researcher will give syringe to the patient and the patient will administer the solution to themself orally prior to entering the operating room.

Dates

Last Verified: 11/30/2017
First Submitted: 04/05/2016
Estimated Enrollment Submitted: 05/11/2016
First Posted: 05/16/2016
Last Update Submitted: 12/27/2017
Last Update Posted: 01/01/2018
Actual Study Start Date: 03/31/2016
Estimated Primary Completion Date: 07/31/2016
Estimated Study Completion Date: 11/30/2017

Condition or disease

Pain

Intervention/treatment

Drug: Methadone

Drug: Placebo

Phase

Phase 2

Arm Groups

ArmIntervention/treatment
Experimental: Methadone
Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
Drug: Methadone
0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
Placebo Comparator: Placebo
Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
Drug: Placebo
equivalent volume (5mL) of syrup given preoperatively

Eligibility Criteria

Ages Eligible for Study 18 Years To 18 Years
Sexes Eligible for StudyAll
Accepts Healthy VolunteersYes
Criteria

Inclusion Criteria:

- presenting for elective first-time CABG cardiac surgery with anticipated extubation within 12 hours

Exclusion Criteria:

- < 18 years of age

- preoperative renal failure requiring dialysis or serum creatinine greater than 176 µmol/L

- significant hepatic dysfunction (liver function tests more than twice the upper limit of normal)

- ejection fraction less than 30%

- corrected QT interval (QTc) on ECG > 440ms for men and 450ms for women

- pulmonary disease necessitating home oxygen therapy

- preoperative requirement for inotropic agents or intra-aortic balloon pump to maintain hemodynamic stability

- emergency surgery

- allergy to methadone

- use of preoperative opioids or recent history of opioid abuse

Outcome

Primary Outcome Measures

1. Pain score (VRS) [24 hours]

Pain score as measured by 0-10 Verbal Rating Score (VRS)

Secondary Outcome Measures

1. Total Morphine Consumption (mg) [72 hours]

Total dose in mg of IV morphine administered via Patient Controlled Analgesia

2. Pain score (VRS) [Up to 72 hours postoperative]

Pain score as measured by 0-10 Verbal Rating Score (VRS)

3. Time to extubation [up to 24 hours postoperative]

Time from start of surgery until removal of endotracheal tube in ICU

4. Level of sedation [up to 72 hours postoperative]

Level of sedation as measured by the Richmond Agitation-Sedation Scale (RASS) in ICU

5. Incidence of opioid-related side effects [up to 72 hours postoperative]

Incidence of as nausea, vomiting, pruritus, hypoventilation, and hypoxia during a seventy-two hour monitoring period

Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge